1 North Waukegan Road
North Chicago, IL 60064-6400
United States
847 932 7900
http://www.abbvie.com
Sector(s): Healthcare
Industry: Drug Manufacturers—General
Full-time employees: 47,000
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Mr. Richard A. Gonzalez | Chairman & CEO | 7.11M | N/A | 1954 |
Dr. Michael E. Severino | Vice Chairman & Pres | 3.98M | N/A | 1966 |
Mr. Robert A. Michael | Exec. VP & CFO | 2.76M | N/A | 1970 |
Ms. Laura J. Schumacher | Vice Chairman of External Affairs, Chief Legal Officer & Corp. Sec. | 4.3M | N/A | 1963 |
Dr. Azita Saleki-Gerhardt | Exec. VP of Operations | N/A | N/A | 1963 |
Dr. Thomas J. Hudson | Sr. VP of R&D and Chief Scientific Officer | N/A | N/A | 1962 |
Ms. Elizabeth Shea | VP of Investor Relations | N/A | N/A | N/A |
Mr. Timothy J. Richmond | Exec. VP & Chief HR Officer | N/A | N/A | 1966 |
Mr. Scott C. Brun M.D. | VP of Scientific Affairs & Head of AbbVie Ventures | N/A | N/A | N/A |
Mr. Henry O. Gosebruch | Exec. VP & Chief Strategy Officer | N/A | N/A | 1973 |
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.
AbbVie Inc.’s ISS governance QualityScore as of 3 December 2020 is 7. The pillar scores are Audit: 9; Board: 6; Shareholder rights: 9; Compensation: 3.